Effects of ulinastatin on coagulation in high-risk patients undergoing off-pump coronary artery bypass graft surgery

Korean Journal of Anesthesiology

Volumn 64, Issue 2, 2013, Pages 105-111

  Kim, Na Young ^a   Shim, Jae Kwang ^a   Bang, Seo Ouk ^a   Sim, Jee Suk ^a   Song, Jong Wook ^a   Kwak, Young Lan ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Coagulability; HsCRP; OPCAB; Ulinastatin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HEPARIN; LEUKOCYTE ELASTASE; MILRINONE; PROTAMINE; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; TROPONIN T; ULINASTATIN;

ADULT; AGED; ARTERY CATHETER; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYSTALLOID; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPOTENSION; INCIDENCE; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; OFF PUMP CORONARY SURGERY; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; STERNOTOMY; THROMBOCYTE COUNT;

EID: 84874610723     PISSN: 20056419     EISSN: 20057563     Source Type: Journal    
DOI: 10.4097/kjae.2013.64.2.105     Document Type: Article

References (30)

1. Nesher N, Frolkis I, Vardi M, Sheinberg N, Bakir I, Caselman F, et al. Higher levels of serum cytokines and myocardial tissue markers during on-pump versus off-pump coronary artery bypass surgery. J Card Surg 2006; 21: 395-402.
2. Kon ZN, Kwon MH, Collins MJ, Kallam S, Sangrampurkar R, Ozeki T, et al. Off-pump coronary artery bypass leads to a regional hypercoagulable state not detectable using systemic markers. Innovations (Phila) 2006; 1: 232-8.
3. Kon ZN, Brown EN, Grant MC, Ozeki T, Burris NS, Collins MJ, et al. Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition. Eur J Cardiothorac Surg 2008; 33: 215-21.
4. Nishiyama T, Hanaoka K. Do the effects of a protease inhibitor, ulinastatin, on elastase release by blood transfusion depend on interleukin 6? Crit Care Med 2001; 29: 2106-10.
5. Bingyang J, Jinping L, Mingzheng L, Guyan W, Zhengyi F. Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response. J Cardiovasc Surg (Torino) 2007; 48: 497-503.
6. Nishiyama T, Yokoyama T, Yamashita K. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery. J Anesth 2006; 20: 179-82.
7. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007; 16: 14-21.
8. Balciunas M, Bagdonaite L, Samalavicius R, Griskevicius L, Vuylsteke A. Pre-operative high sensitive C-reactive protein predicts cardiovascular events after coronary artery bypass grafting surgery: a prospective observational study. Ann Card Anaesth 2009; 12: 127-32.
9. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004; 47: 305-14.
10. Stepień E, Plicner D, Branicka A, Stankiewicz E, Pazdan A, Sniezek-Maciejewska M, et al. Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease. Pol Arch Med Wewn 2007; 117: 297-305.
11. Ikeda U, Yamamoto K, Shimada K. Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy. Clin Cardiol 1997; 20: 7-10.
12. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001; 15: 101-5.
13. Sato Y, Ishikawa S, Otaki A, Takahashi T, Hasegawa Y, Suzuki M, et al. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury. Jpn J Thorac Cardiovasc Surg 2000; 48: 428-34.
14. Inoue K, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 2010; 19: 513-20.
15. Park KH, Lee KH, Kim H, Hwang SO. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci 2010; 25: 128-34.
16. Okida M, Masako O, Maruya H, Higashi T, Yukaya H. Intraoperative changes in blood coagulation and the effectiveness of ulinastatin during liver resection. J Anesth 1991; 5: 43-7.
17. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9.
18. Bjork P, Axelsson L, Bergenfeldt M, Ohlsson K. Influence of plasma protease inhibitors and the secretory leucocyte protease inhibitor on leucocyte elastase-induced consumption of selected plasma proteins in vitro in man. Scand J Clin Lab Invest 1988; 48: 205-11.
19. Madoiwa S, Tanaka H, Nagahama Y, Dokai M, Kashiwakura Y, Ishiwata A, et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res 2011; 127: 349-55.
20. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-92.
21. Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006; 34: 1351-7.
22. MacGillivray TE, Vlahakes GJ. Patency and the pump--the risks and benefits of off-pump CABG. N Engl J Med 2004; 350: 3-4.
23. Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, van Oeveren W, Ebels T. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg 1999; 67: 1370-5.
24. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38: 41-54.
25. Hedman A, Larsson PT, Alam M, Wallen NH, Nordlander R, Samad BA. CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol 2007; 120: 108-14.
26. Thachil J. The prothrombotic potential of platelet factor 4. Eur J Intern Med 2010; 21: 79-83.
27. Lee JY, Lee JY, Chon JY, Moon HS, Hong SJ. The effect of ulinastatin on hemostasis in major orthopedic surgery. Korean J Anesthesiol 2010; 58: 25-30.
28. Jonsson-Berling BM, Ohlsson K. Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scand J Clin Lab Invest 1991; 51: 549-57.
29. Wang GY, Qiu HB, Zhan SG, Li LH. Protection of ulinastatin against myocardial injury induced by off-pump coronary artery bypass graft surgery: report of 24 cases. Zhonghua Yi Xue Za Zhi 2007; 87: 2502-4.
30. Montalescot G, Hulot JS, Collet JP. Antiplatelet therapy and coronary artery bypass graft surgery a fallow land. J Am Coll Cardiol 2010; 56: 2003-5.